Bayer, Chattem Sneeze At NAD Decision On Claritin And Nasacort Comparison
This article was originally published in The Tan Sheet
Executive Summary
NAD’s review of Bayer’s Claritin and Claritin-D ads upsets Bayer and challenger Chattem as both appeal the decision to the National Advertising Review Board. Bayer argues it supports the claim nothing “works faster” than Claritin-D, while Chattem says Bayer does not support claiming Claritin-D “starts to work on allergies in 30 minutes.”
You may also be interested in...
Bayer Supports Claritin-D Indications Claim, Not Superiority Over GSK's Flonase
Bayer supports making an “8 versus 6 FDA-approved indications” comparison with GSK's Flonase ,but it fails when suggesting Flonase doesn't relieve "sinus congestion and pressure” and “itchy throat” based only on GSK's competing product not receiving FDA approval for those indications, says NAD.
Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
Claims that Sanofi's Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication fail a US
Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
Claims that Sanofi's Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication fail a US